One thing Neuren has going for it is that the revenues will be in USD and in the doomsday scenario i.e. a China hard landing, the Aussie dollar would depreciate against USD making Neuren's market cap cheaper and cheaper for a Big Pharma acquisition without the share price itself failing. So while China is up 1.6% today, and Monday is likely to be a Green day in Australia, NEU's USD exposure provides a good buffer against a hard landing in China.
The other thing I like about the Orphan drug space is a very stable/predictable cash-flow scenario across all economic cycles, compared to most other industries which are boom-bust. NNZ-2566 (yes, I am old school) targets diseases with terrible side effects, there is no alternate treatment and the quality of life is terrible for the patients, so no matter the economy market insurers pay out and market share %/revenue will remain unchanged.
One thing Neuren has going for it is that the revenues will be...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.17 |
Change
0.070(0.35%) |
Mkt cap ! $2.578B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $4.102M | 202.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 249 | $20.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.31 | 790 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |